CA3053991A1 - Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases - Google Patents
Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases Download PDFInfo
- Publication number
- CA3053991A1 CA3053991A1 CA3053991A CA3053991A CA3053991A1 CA 3053991 A1 CA3053991 A1 CA 3053991A1 CA 3053991 A CA3053991 A CA 3053991A CA 3053991 A CA3053991 A CA 3053991A CA 3053991 A1 CA3053991 A1 CA 3053991A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- cndot
- aprocitentan
- diuretic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims abstract 5
- 239000004480 active ingredient Substances 0.000 title abstract 3
- 102000002045 Endothelin Human genes 0.000 title abstract 2
- 108050009340 Endothelin Proteins 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 title abstract 2
- DKULOVKANLVDEA-UHFFFAOYSA-N ACT-132577 Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)N)=NC=NC=1OCCOC1=NC=C(Br)C=N1 DKULOVKANLVDEA-UHFFFAOYSA-N 0.000 claims abstract 23
- 229940070148 aprocitentan Drugs 0.000 claims abstract 22
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 12
- 239000002934 diuretic Substances 0.000 claims abstract 11
- 230000001882 diuretic effect Effects 0.000 claims abstract 11
- 229940127291 Calcium channel antagonist Drugs 0.000 claims abstract 6
- 239000000480 calcium channel blocker Substances 0.000 claims abstract 6
- 239000003087 receptor blocking agent Substances 0.000 claims abstract 6
- 239000005458 thiazide-like diuretic Substances 0.000 claims abstract 6
- 150000003839 salts Chemical class 0.000 claims 37
- 239000002552 dosage form Substances 0.000 claims 14
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims 11
- 229960002003 hydrochlorothiazide Drugs 0.000 claims 11
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 9
- 229960000528 amlodipine Drugs 0.000 claims 9
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims 9
- 208000020832 chronic kidney disease Diseases 0.000 claims 9
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 9
- 229960004699 valsartan Drugs 0.000 claims 9
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 claims 7
- 229960001523 chlortalidone Drugs 0.000 claims 7
- 206010020772 Hypertension Diseases 0.000 claims 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- 238000010586 diagram Methods 0.000 claims 5
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 3
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 3
- 208000007530 Essential hypertension Diseases 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 230000007211 cardiovascular event Effects 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 230000005855 radiation Effects 0.000 claims 3
- 208000015658 resistant hypertension Diseases 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 229940118365 Endothelin receptor antagonist Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002308 endothelin receptor antagonist Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017054489 | 2017-02-27 | ||
| EPPCT/EP2017/054489 | 2017-02-27 | ||
| EP2017061487 | 2017-05-12 | ||
| EPPCT/EP2017/061487 | 2017-05-12 | ||
| PCT/EP2017/078371 WO2018153513A1 (en) | 2017-02-27 | 2017-11-06 | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3053991A1 true CA3053991A1 (en) | 2018-08-30 |
Family
ID=60268369
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3053991A Pending CA3053991A1 (en) | 2017-02-27 | 2017-11-06 | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
| CA3053994A Pending CA3053994A1 (en) | 2017-02-27 | 2018-02-26 | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3053994A Pending CA3053994A1 (en) | 2017-02-27 | 2018-02-26 | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US11174247B2 (enExample) |
| EP (3) | EP3658140B1 (enExample) |
| JP (3) | JP7223701B2 (enExample) |
| KR (3) | KR102700778B1 (enExample) |
| CN (3) | CN110325186A (enExample) |
| AU (2) | AU2017400276B2 (enExample) |
| BR (2) | BR112019017658A2 (enExample) |
| CA (2) | CA3053991A1 (enExample) |
| CL (3) | CL2019002464A1 (enExample) |
| DK (2) | DK3658140T3 (enExample) |
| ES (2) | ES3038007T3 (enExample) |
| FI (2) | FI3658140T3 (enExample) |
| HR (2) | HRP20250921T1 (enExample) |
| HU (2) | HUE072288T2 (enExample) |
| IL (4) | IL268850B2 (enExample) |
| LT (2) | LT3658140T (enExample) |
| MA (2) | MA49664A (enExample) |
| MX (3) | MX392313B (enExample) |
| MY (2) | MY199557A (enExample) |
| NZ (1) | NZ757344A (enExample) |
| PH (2) | PH12019501938A1 (enExample) |
| PL (2) | PL3658140T3 (enExample) |
| PT (2) | PT3658140T (enExample) |
| RS (2) | RS67082B1 (enExample) |
| SG (3) | SG11201907435PA (enExample) |
| SI (2) | SI3658140T1 (enExample) |
| TW (2) | TWI786089B (enExample) |
| UA (1) | UA126122C2 (enExample) |
| WO (2) | WO2018153513A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016025671A2 (en) * | 2014-08-14 | 2016-02-18 | Vivus, Inc. | Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist |
| SI3658140T1 (sl) | 2017-02-27 | 2025-08-29 | Idorsia Pharmaceuticals Ltd | Kombinacije aprocitentana z nadaljnjimi učinkovinami za zdravljenje rezistentne hipertenzije |
| EP3716979B1 (en) * | 2017-11-30 | 2025-04-09 | Idorsia Pharmaceuticals Ltd | Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases |
| JP7312262B2 (ja) | 2018-09-28 | 2023-07-20 | フロー メディカル コーポレイション | カテーテル装置 |
| BR112021011999A2 (pt) | 2018-12-21 | 2021-09-08 | Actelion Pharmaceuticals Ltd | Composição farmacêutica para o tratamento de hipertensão arterial pulmonar |
| TW202042818A (zh) | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
| CN112569357B (zh) * | 2019-09-30 | 2023-03-28 | 深圳奥萨制药有限公司 | 双重内皮素受体拮抗剂与利尿剂的组合物 |
| CN112679441A (zh) * | 2019-10-18 | 2021-04-20 | 普济生物科技（台州）有限公司 | 阿普昔腾坦的晶型、制备方法及其用途 |
| EP4056182A1 (en) * | 2019-11-07 | 2022-09-14 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of aprocitentan, preparation method therefor and use thereof |
| US12421214B2 (en) | 2020-05-21 | 2025-09-23 | Assia Chemical Industries Ltd. | Solid state forms of aprocitentan and process for preparation thereof |
| PH12023550025A1 (en) | 2020-07-10 | 2024-03-11 | Astrazeneca Ab | Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease |
| CN114644595A (zh) * | 2020-12-19 | 2022-06-21 | 普济生物科技（台州）有限公司 | 阿普昔腾坦的无定型态、其药物组合物和用途 |
| WO2023111797A1 (en) * | 2021-12-17 | 2023-06-22 | Janssen Biotech, Inc. | Pyrimidine sulfamide derivatives and process for manufacturing them |
| CN119255805A (zh) | 2022-05-22 | 2025-01-03 | 爱杜西亚药品有限公司 | 用于治疗高血压的阿普昔腾坦 |
| WO2023227721A1 (en) | 2022-05-25 | 2023-11-30 | Idorsia Pharmaceuticals Ltd | Crystalline forms of sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide |
| WO2024140425A1 (zh) * | 2022-12-30 | 2024-07-04 | 苏州科睿思制药有限公司 | 一种阿普昔腾坦晶型及其制备方法和用途 |
| KR20250152723A (ko) | 2024-04-16 | 2025-10-24 | 경북대학교 산학협력단 | 신규한 피리미딘 유도체 화합물 및 이의 용도 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59409631D1 (de) * | 1993-07-15 | 2001-02-15 | Hoffmann La Roche | Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält |
| HU229403B1 (en) | 2000-12-18 | 2013-12-30 | Actelion Pharmaceuticals Ltd | Novel sulfamides and their use as endothelin receptor antagonists |
| EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| US20070196510A1 (en) | 2006-02-17 | 2007-08-23 | Gerber Michael J | Method for treating resistant hypertension |
| WO2007146900A2 (en) | 2006-06-15 | 2007-12-21 | Gilead Colorado, Inc. | Antihypertensive therapy method |
| PE20120542A1 (es) | 2006-06-27 | 2012-05-14 | Novartis Ag | Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas |
| MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
| JP2010536880A (ja) * | 2007-08-22 | 2010-12-02 | ギリード・コロラド・インコーポレーテッド | 糖尿病の合併症のための療法 |
| CN102614189B (zh) * | 2012-04-17 | 2014-10-22 | 北京哈三联科技股份有限公司 | 含缬沙坦、氨氯地平和氢氯噻嗪的微丸药物组合 |
| EP2907811A1 (en) * | 2014-02-14 | 2015-08-19 | Actelion Pharmaceuticals Ltd. | Process for manufacturing pyrimidine sulfamide derivatives |
| EP3215138A4 (en) | 2014-11-07 | 2018-11-21 | AbbVie Inc. | Methods of treating ckd using predictors of fluid retention |
| WO2017185142A1 (en) | 2016-04-29 | 2017-11-02 | Adelaide Research & Innovation Pty Ltd | Method for preventing and/or treating atrial fibrillation |
| SI3658140T1 (sl) | 2017-02-27 | 2025-08-29 | Idorsia Pharmaceuticals Ltd | Kombinacije aprocitentana z nadaljnjimi učinkovinami za zdravljenje rezistentne hipertenzije |
| EP3716979B1 (en) | 2017-11-30 | 2025-04-09 | Idorsia Pharmaceuticals Ltd | Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases |
| BR112021011999A2 (pt) * | 2018-12-21 | 2021-09-08 | Actelion Pharmaceuticals Ltd | Composição farmacêutica para o tratamento de hipertensão arterial pulmonar |
-
2017
- 2017-11-06 SI SI201731613T patent/SI3658140T1/sl unknown
- 2017-11-06 MX MX2019010222A patent/MX392313B/es unknown
- 2017-11-06 JP JP2019546291A patent/JP7223701B2/ja active Active
- 2017-11-06 FI FIEP17794712.4T patent/FI3658140T3/fi active
- 2017-11-06 EP EP17794712.4A patent/EP3658140B1/en active Active
- 2017-11-06 MA MA049664A patent/MA49664A/fr unknown
- 2017-11-06 DK DK17794712.4T patent/DK3658140T3/da active
- 2017-11-06 KR KR1020237016438A patent/KR102700778B1/ko active Active
- 2017-11-06 IL IL268850A patent/IL268850B2/en unknown
- 2017-11-06 NZ NZ757344A patent/NZ757344A/en unknown
- 2017-11-06 UA UAA201909965A patent/UA126122C2/uk unknown
- 2017-11-06 KR KR1020197028199A patent/KR102568472B1/ko active Active
- 2017-11-06 AU AU2017400276A patent/AU2017400276B2/en active Active
- 2017-11-06 MY MYPI2019004938A patent/MY199557A/en unknown
- 2017-11-06 CA CA3053991A patent/CA3053991A1/en active Pending
- 2017-11-06 US US16/489,227 patent/US11174247B2/en active Active
- 2017-11-06 HU HUE17794712A patent/HUE072288T2/hu unknown
- 2017-11-06 RS RS20250776A patent/RS67082B1/sr unknown
- 2017-11-06 LT LTEPPCT/EP2017/078371T patent/LT3658140T/lt unknown
- 2017-11-06 IL IL315563A patent/IL315563A/en unknown
- 2017-11-06 CN CN201780087445.XA patent/CN110325186A/zh active Pending
- 2017-11-06 PL PL17794712.4T patent/PL3658140T3/pl unknown
- 2017-11-06 SG SG11201907435PA patent/SG11201907435PA/en unknown
- 2017-11-06 HR HRP20250921TT patent/HRP20250921T1/hr unknown
- 2017-11-06 PT PT177947124T patent/PT3658140T/pt unknown
- 2017-11-06 BR BR112019017658-6A patent/BR112019017658A2/pt not_active Application Discontinuation
- 2017-11-06 ES ES17794712T patent/ES3038007T3/es active Active
- 2017-11-06 WO PCT/EP2017/078371 patent/WO2018153513A1/en not_active Ceased
-
2018
- 2018-02-26 HR HRP20241461TT patent/HRP20241461T1/hr unknown
- 2018-02-26 SG SG11201907604UA patent/SG11201907604UA/en unknown
- 2018-02-26 RS RS20241269A patent/RS66200B1/sr unknown
- 2018-02-26 ES ES21202979T patent/ES3006308T3/es active Active
- 2018-02-26 TW TW107106403A patent/TWI786089B/zh active
- 2018-02-26 CA CA3053994A patent/CA3053994A1/en active Pending
- 2018-02-26 SI SI201831162T patent/SI4014976T1/sl unknown
- 2018-02-26 JP JP2019546286A patent/JP2020508338A/ja active Pending
- 2018-02-26 CN CN202311718027.XA patent/CN117946011A/zh active Pending
- 2018-02-26 HU HUE21202979A patent/HUE069231T2/hu unknown
- 2018-02-26 MY MYPI2019004939A patent/MY208610A/en unknown
- 2018-02-26 EP EP21202979.7A patent/EP4014976B1/en active Active
- 2018-02-26 TW TW111142832A patent/TWI854353B/zh active
- 2018-02-26 WO PCT/EP2018/054627 patent/WO2018154101A1/en not_active Ceased
- 2018-02-26 PT PT212029797T patent/PT4014976T/pt unknown
- 2018-02-26 EP EP18708945.3A patent/EP3585391A1/en not_active Withdrawn
- 2018-02-26 KR KR1020197028200A patent/KR102577375B1/ko active Active
- 2018-02-26 DK DK21202979.7T patent/DK4014976T3/da active
- 2018-02-26 PL PL21202979.7T patent/PL4014976T3/pl unknown
- 2018-02-26 FI FIEP21202979.7T patent/FI4014976T3/fi active
- 2018-02-26 US US16/489,194 patent/US10919881B2/en active Active
- 2018-02-26 AU AU2018225309A patent/AU2018225309B2/en active Active
- 2018-02-26 SG SG10202111695RA patent/SG10202111695RA/en unknown
- 2018-02-26 CN CN201880014146.8A patent/CN110381948A/zh active Pending
- 2018-02-26 LT LTEP21202979.7T patent/LT4014976T/lt unknown
- 2018-02-26 MX MX2019010221A patent/MX2019010221A/es unknown
- 2018-02-26 BR BR112019017644-6A patent/BR112019017644A2/pt not_active Application Discontinuation
- 2018-02-26 MA MA047596A patent/MA47596A/fr unknown
- 2018-02-26 IL IL297993A patent/IL297993B2/en unknown
-
2019
- 2019-08-22 PH PH12019501938A patent/PH12019501938A1/en unknown
- 2019-08-22 PH PH12019501937A patent/PH12019501937A1/en unknown
- 2019-08-22 IL IL26885219A patent/IL268852A/en unknown
- 2019-08-27 CL CL2019002464A patent/CL2019002464A1/es unknown
- 2019-08-27 CL CL2019002470A patent/CL2019002470A1/es unknown
- 2019-08-27 MX MX2021007184A patent/MX2021007184A/es unknown
-
2020
- 2020-06-30 CL CL2020001762A patent/CL2020001762A1/es unknown
-
2021
- 2021-01-12 US US17/146,801 patent/US11680058B2/en active Active
- 2021-09-10 US US17/472,349 patent/US11787782B2/en active Active
-
2022
- 2022-12-16 JP JP2022201112A patent/JP7520951B2/ja active Active
-
2023
- 2023-05-17 US US18/319,402 patent/US12297189B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3053991A1 (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| CA3083327A1 (en) | Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases | |
| US20230390241A1 (en) | Dash inhibitors, and uses related thereto | |
| JP2020508339A5 (enExample) | ||
| JP2020508338A5 (enExample) | ||
| ES2968541T3 (es) | Tratamiento de enfermedades cardiovasculares | |
| RU2010123027A (ru) | Фармацевтические композиции двойного действия на основе надмолекулярных структур антагониста/блокатора рецепторов ангиотензина (arb) и ингибитора нейтральной эндопептидазы (nep) | |
| JP2019517542A5 (enExample) | ||
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| US20230372372A1 (en) | Combination therapies using caspase-1 dependent anticancer agents and pge2 antagonists | |
| JP6509729B2 (ja) | 慢性腎臓病の進行抑制又は改善剤 | |
| WO2017006254A1 (en) | Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist | |
| JP2019509309A5 (enExample) | ||
| WO2016066851A1 (en) | Combination for the treatment of conditions involving muscular pain | |
| JP2006517557A (ja) | 脳卒中発作予防のための、アセチルサリチル酸およびアンジオテンシンｉｉ拮抗薬と組み合わせたジピリダモールの使用 | |
| US11559537B2 (en) | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | |
| TWI354553B (en) | Drug for glomerular diseases | |
| TW201737909A (zh) | 用以腎臟病之治療的醫藥 | |
| MX2012013054A (es) | Combinacion de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso. | |
| RU2014125702A (ru) | Фармацевтическая композиция для профилактики или лечения гиперлипидемии | |
| WO2005053687A1 (en) | Combination of organic compounds | |
| EP3073995B1 (en) | Pharmaceutical formulation comprising losartan potassium and chlorthalidone | |
| KR20200048516A (ko) | 복합제 의약 조성물 | |
| WO2020013781A3 (en) | Synergistic effect of flurbiprofen and a gastro protective agent for the treatment of pain and inflammation | |
| TH2001003051A (th) | การรวมกันของอนุพันธ์ 4-ไพริมิดีนซัลฟาไมด์กับตัวยับยั้ง sglt-2 สำหรับการบำบัดโรคที่เกี่ยวข้องกับเอนโดทีลิน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220929 |
|
| EEER | Examination request |
Effective date: 20220929 |
|
| EEER | Examination request |
Effective date: 20220929 |
|
| EEER | Examination request |
Effective date: 20220929 |